Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of…
The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca, have revolutionized the therapeutic landscape of platinum-…
Primary, or essential, hypertension is defined as persistently elevated blood pressure without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., coronary…
Nocturnal polyuria, a key contributing factor of nocturia in adults, is characterized by overproduction of urine at night. Changes in lifestyle and circadian rhythms, and conditions such as…
Multiple treatment options—topical therapies, oral drugs, phototherapy, and biologics—are available to treat psoriasis. In particular, the approval of biologics other than TNF-α inhibitors (…
Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disorder that leads to progressive muscle wasting and weakness. The typical survival time is three to five years from onset. The…
Cancer pain is a complex form of chronic pain to treat because it typically involves mixed nociceptive and neuropathic pain resulting from multiple causes (e.g., chemotherapy, metastases)…
Numerous antidepressant therapies are available to treat major depressive disorder (MDD), many of which have long been generic and are entrenched in medical practice. However, most current…
Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just in the past year…
MARKET OUTLOOK Rheumatoid arthritis (RA) is characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue damage and cartilage and bone…
PAH is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial unmet need remains for more-…
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: the tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira,…
The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has resulted in a highly segmented space dominated by…
Postoperative pain comprises one of the larger segments of the total market for acute pain therapies, and it has experienced substantial growth over the past decade due to the market uptake of…